High Rise: Cannabis MSOs, Products & Market Analysis cover art

High Rise: Cannabis MSOs, Products & Market Analysis

High Rise: Cannabis MSOs, Products & Market Analysis

Written by: Headset Inc.
Listen for free

LIMITED TIME OFFER | Get 2 Months for ₹5/month

About this listen

 A laid-back, data-backed discussion on the cannabis market with notable industry leaders.© 2023 High Rise: Cannabis MSOs, Products & Market Analysis Economics Personal Finance
Episodes
  • E169: Vape Pens vs. Flower in California, Texas Hemp Ban & State Market Updates

    E169: Vape Pens vs. Flower in California, Texas Hemp Ban & State Market Updates
    Mar 17 2026
    Cy and Emily dive into the data showing vapor pens closing in on flower as the top cannabis category in California — with only a $5M gap in February 2026 sales. They explore the Gen Z consumer shift driving vape growth, then cover Texas banning smokeable hemp through new THCA testing rules affecting 9,000 stores, plus updates from Florida, New York, and Massachusetts markets.

    Headset
    Show More Show Less
    57 mins
  • The $28 Billion Ban: Hemp's Last Stand | The High-Rise Ep. 168

    The $28 Billion Ban: Hemp's Last Stand | The High-Rise Ep. 168
    Mar 3 2026
    The FDA just blew past a congressionally mandated deadline on hemp regulation — and a $28 billion industry is counting down to a November ban. Missouri is already passing state-level bans, while New York wants liquor stores selling cannabis drinks. Illinois posted its first-ever annual sales decline. The DOJ says cannabis users can't own guns even after rescheduling. Hawaii's trying "legalization lite." Plus: Texas ballot questions, Virginia retail sales, NJ wholesale crashes, and four states pushing medical marijuana into hospitals. We've got the Headset data to make sense of all of it. This is The High-Rise.Chapters:00:00 — Welcome Back to The High-Rise05:24 — News Roundup: Hemp Ban & FDA Deadline10:56 — Illinois Posts First-Ever Sales Decline15:58 — Texas Cannabis Ballot & Democratic Primary19:11 — Virginia Retail Marijuana Sales Bill20:48 — New Jersey Wholesale Prices Crater25:29 — Missouri Passes Hemp THC Ban28:01 — New York: Cannabis Beverages in Liquor Stores31:29 — NYC Mayor Projects Rising Cannabis Tax Revenue34:12 — DOJ Urges Gun Ban for Cannabis Users37:17 — Hawaii Approves Limited Legalization39:20 — Four States Advance Medical MJ in Hospitals41:22 — Deep Dive: The Hemp Ban — Who Wins, Who Loses55:10 — Closing & What's NextHosts: Cy Scott (Headset) & Emily Paxhia (Poseidon)Data powered by Headset: https://www.headset.io

    Headset
    Show More Show Less
    56 mins
  • E167 - Bluegrass Bud: Kentucky Medical Cannabis Arrives

    E167 - Bluegrass Bud: Kentucky Medical Cannabis Arrives
    Feb 5 2025

    The Bluegrass State is joining the green rush—but in true Kentucky fashion, they're doing it their own way. Join Emily Paxhia (Poseidon) and Cy Scott (Headset) as they break down Kentucky's cautious entry into medical cannabis, and what it means for operators, investors, and entrepreneurs.

    In this episode, our hosts dive deep into:

    • Kentucky's unique approach to medical cannabis (spoiler: leave your rolling papers at home)
    • Why most licenses went to out-of-state operators, and what that means for the market
    • How Kentucky stacks up against Missouri, Mississippi, and Florida
    • Where the real opportunities lie for entrepreneurs who missed the licensing lottery
    • Market projections and investment potential that might surprise you

    Whether you're an MSO executive, an ancillary business owner, or an investor eyeing the next frontier market, this episode offers critical insights into one of the newest medical markets in the United States. Plus, Emily and Cy share their signature market analysis on whether Kentucky could follow Florida's highly profitable path or face Mississippi's growing pains.

    Pour yourself a bourbon (or your favorite alternative), and join us for an hour of market intelligence, strategic insights, and maybe even a table flip or two. 🥃

    Headset
    Show More Show Less
    39 mins
No reviews yet